ozempic semaglutide (semaglutide) for the Treatment of Type 2 Diabetes Weight-loss jab could be made

Weight Disord

The SURMOUNT-5 trial , as described by Aronne and colleagues, compared tirzepatide (Zepbound) to semaglutide (Wegovy), a mono GLP-1, in 751 adults living with obesity with one weight-related medical issue but without diabetes

Cardiovascular risk reduction, while present, follows a less linear relationship

A review of GLP-1 receptor agonists: evolution and advancement, through the lens of randomized controlled trials

In controlled clinical trials of metformin of 29 weeks duration, a decrease to subnormal levels of previously normal serum vitamin B12 levels was observed in approximately 7% of patients

Commercial expectations surrounding this sector continue to accelerate